Rhonda Hellums
Board Member
Silence Therapeutics plc (SLN)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Rhonda Hellums
Rhonda Hellums is recorded as Board Member and CFO at Silence Therapeutics plc (SLN). Silence Therapeutics plc reported in an 8-K filed December 22, 2025 that Rhonda Hellums was appointed Executive Director, effective December 18, 2025. The proxy statement of Silence Therapeutics plc reports total compensation of $1,150,923 for Rhonda Hellums in fiscal 2025, including a base salary of $490,000. Disclosed compensation is on record for 4 fiscal years. Rhonda Hellums has spoken on 4 earnings calls across 1 company, most recently for Silence Therapeutics plc on February 27, 2025.
“On December 18, 2025, the Board of Directors (the "Board") of Silence Therapeutics plc (the "Company") appointed Rhonda Hellums, the Company's Executive Vice President and Chief Financial Officer, to the Board, effectively immediately.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
-
Current
Start not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Silence Therapeutics plc
Other people whose current roles at this company are on record from its filings.
- Craig Tooman CEO
- Iain Ross CEO, Chairman
- Dave Lemus Board Member
- James Ede-Golightly Board Member
- Tim McInerney Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Silence Therapeutics plc (SLN) | Executive Vice President, Chief Financial Officer | $490,000 | $1,150,923 |
| 2024 | Silence Therapeutics plc (SLN) | Executive Vice President, Chief Financial Officer | $466,013 | $1,662,818 |
| 2023 | Silence Therapeutics plc (SLN) | Executive Vice President, Chief Financial Officer | $430,500 | $3,084,844 |
| 2022 | Silence Therapeutics plc (SLN) | Executive Vice President, Chief Financial Officer | $403,958 | $2,383,489 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.